Abstract
The poor intracellular uptake and non-specific binding of anticancer drugs into cancer cells are the bottlenecks in cancer therapy. Nanocarrier platforms provide the opportunities to improve the drug efficacy. Here we show a carbon-based nanomaterial nanodiamond (ND) that carried paclitaxel (PTX), a microtubule inhibitor, and cetuximab (Cet), a specific monoclonal antibody against epidermal growth factor receptor (EGFR), inducing mitotic catastrophe and tumor inhibition in human colorectal cancer (CRC). ND-PTX blocked the mitotic progression, chromosomal separation, and induced apoptosis in the CRC cells; however, NDs did not induce these effects. Conjugation of ND-PTX with Cet (ND-PTX-Cet) was specifically binding to the EGFR-positive CRC cells and enhanced the mitotic catastrophe and apoptosis induction. Besides, ND-PTX-Cet markedly decreased tumor size in the xenograft EGFR-expressed human CRC tumors of nude mice. Moreover, ND-PTX-Cet induced the mitotic marker protein phospho-histone 3 (Ser10) and apoptotic protein active-caspase 3 for mitotic catastrophe and apoptosis. Taken together, this study demonstrated that the co-delivery of PTX and Cet by ND enhanced the effects of mitotic catastrophe and apoptosis in vitro and in vivo, which may be applied in the human CRC therapy.
Similar content being viewed by others
Introduction
Colorectal cancer (CRC) is one of the leading causes of morbidity and mortality worldwide1, 2. Specific molecular genes and proteins of CRC progression have been developed for therapeutic targets, including growth factor receptors, proliferation signaling, cell cycle progression and angiogenesis3, 4. Chemotherapeutic drugs and targeting antibodies can be used in treating CRC patients5, 6. However, the poor intracellular uptake, non-specific binding and limited circulation stability of those drugs declined its efficacy in cancer therapy.
Epidermal growth factor receptor (EGFR) of CRC cells is a crucial target for cancer therapy. Cetuximab (Cet) is a human/murine chimeric monoclonal antibody of EGFR with an immunoglobulin G1 Fc isotype7 that was treated in the metastatic CRC with the EGFR expression8. Cet can inhibit EGFR function by binding to the extracellular domain of EGFR and blocking ligand interaction9. Nonetheless, the drug resistance of Cet has been reported in clinical CRC patients10, 11.
Paclitaxel (PTX) is a microtubule inhibitor that can treat a variety of human cancers12. The mechanism of PTX is disturbing microtubule dynamics and inducing mitotic catastrophe13,14,15. Mitotic catastrophe is one of cell death types as a result of abnormal chromosome segregation by mitosis blockage16,17,18. The mitotic catastrophe in cancer cells induced by anticancer drugs contributed tumor suppression16,17,18. Moreover, PTX has drawbacks such as dose-limiting toxicity and drug resistance in cancer therapy.
The drug delivery systems by nanomaterials furnish the opportunity in improving the drug efficacy. Nanodiamond (ND) is a carbon-based nanomaterial without obvious cytotoxic effects in cellular19,20,21,22,23,24,25 and animals models26,27,28,29. The surface of NDs can be functionalized with chemicals or bio-molecules for various biomedical applications, including bio-labeling and drug delivery30,31,32,33,34,35,36,37,38,39. ND covalently linked with PTX was effective in drug delivery and tumor inhibition in human lung cancer35, 40. In this study, the co-delivery of Cet and PTX by ND enhances the mitotic catastrophe and tumor inhibition in the EGFR-expressed CRC.
Results
ND-PTX induces apoptosis in various human CRC cell lines
Previous studies have indicated that NDs did not induce any obvious cytotoxic effects19,20,21,22,23,24,25, 29. We confirmed that NDs did not induce cytotoxic effects, including the cellular morphology and growth ability (Fig. 1a ) and the cell viability (Fig. 1b ) in various human CRC cell lines, HCT116, SW620 and RKO. We manipulated ND by covalently conjugated with PTX induced the blockage of lung tumor growth in vitro and in vivo 35. Nanocomplexes of PTX and NDs enhanced aqueous dispensability and drug retention in cancer cells41. Treatment with ND-PTX (0.1–10 μg/mL for 48 h) significantly reduced the cell viability in a concentration-dependent manner in HCT116, SW620 and RKO cells (Fig. 1c). Moreover, ND-PTX induced the cell death; however, ND alone did not induce these effects. (Supplementary Figure S1). We also compared the cell viability after treatment with PTX alone and ND-PTX, which contained similar concentrations to PTX, in the above cancer cell lines. Both PTX and ND-PTX could reduce the cell viability in the HCT116, SW620 and RKO cells (Supplementary Figure S2a and S2b). However, ND-PTX partially increased the reduction of cell viability by comparison with PTX alone. In addition, we confirmed that ND-PTX induced the cellular morphology of mitotic round up and apoptotic cells can be observed under a phase contrast microscope by time-lapse recording (Supplementary Figure S3 and Supporting video 1).
The uptake ability of ND-PTX in CRC cells was performed by flow cytometry. Treatment with ND-PTX (0.1–1 μg/mL for 48 h) elevated the fluorescence intensities of the cells in a concentration-dependent manner (Supplementary Figure S4). Meanwhile, ND-PTX significantly increased the sub-G1 fractions indicating apoptotic cell populations (Fig. 2a and b). We further confirmed ND-PTX-induced apoptosis levels by Annexin V-FITC and PI staining analysis. The population of Annexin V+/PI− cells represents cells undergoing early apoptosis (lower right), whereas the fraction of Annexin V+/PI+ cells is undergoing late apoptosis (upper right). ND-PTX increased the percentages of early and late apoptosis in CRC cells (Fig. 2c). Quantification data show that ND-PTX induced total apoptosis levels in a concentration-dependent manner (Fig. 2d). The apoptotic proteins including the active caspase 3 and the cleaved PARP were induced by ND-PTX (Fig. 2e).
ND-PTX induces mitotic catastrophe
PTX disturbs microtubule dynamics by stabilizing the microtubule polymerization, which leads to mitotic catastrophe13,14,15. Histone phosphorylation is highly related to chromosome function during mitosis42. The phosphorylation of histone 3 (Ser10) (p-H3S10) is a hallmark of mitosis that begins during prophase, reaches maximum levels in metaphase43. As shown in Fig. 3a, ND-PTX (0.1–1 μg/mL for 24 h) increased the protein levels of p-H3S10 via a concentration-dependent manner in CRC cells. The quantified data showed that ND-PTX significantly increased the p-H3S10 proteins (Fig. 3b). Actin is an internal control protein that was not altered by ND-PTX treatment. To further confirm whether the ND-PTX-induce the increase of p-H3S10 proteins and microtubule inhibition, the cells were subjected to immunofluorescence staining and confocal microscopy. Treatment with ND-PTX (0.5 μg/mL for 24 h) increased the protein level of p-H3S10 (Fig. 3c, arrows). Moreover, ND-PTX blocked spindle formation and induced mitotic arrest cells (Fig. 3c, stars). ND-PTX significantly increased the mitotic index (percentage of counting mitotic cell number/total cell number) of ~75% (Fig. 3d). The abnormal spindle formation (stars) and chromosome segregation (arrows) were induced by ND-PTX (green) (Fig. 4).
ND-PTX suppresses xenograft human CRC tumors in nude mice
To evaluate the antitumor ability of ND-PTX in CRC in vivo, the effect of ND-PTX on the xenografted human CRC tumors in nude mice was examined. RKO cells were subcutaneously injected into the nude mice for 10 days and then treated with 50 mg/kg of ND-PTX three times for every 3 days. Figure 5a shows that the tumor volumes were significantly reduced in the ND-PTX treated groups by comparison with the control groups. In the control groups, the average tumor volume was 1218.19 mm3 (Fig. 5b); however, the average tumor volume in the ND-PTX treated groups was reduced to 186.23 mm3 (Fig. 5b). Besides, the tumor tissues sacrificed from mice were examined the p-H3S10 protein levels by western blot. ND-PTX significantly increased the protein levels of p-H3S10 in the xenografted tumors (Fig. 5c and d). Actin is an internal control protein that did not alter following treatment with ND-PTX.
ND-PTX-Cet binds selectively to the EGFR-expressed CRC cells
Figure 6a shows a model of the conjugation of ND-PTX-Cet. The surface charge of Cet, ND-PTX and ND-PTX-Cet was analyzed by Zeta potential instrument. The surface charge of Cet and ND-PTX was 4.01 ± 0.9 and −20.7 ± 0.96, respectively. The average surface charge was −4.2 ± 2.4 when ND-PTX bound with Cet through electrostatic interaction (Fig. 6b). HCT116 cells highly expressed EGFR proteins while SW620 did not express EGFR proteins analyzed by western blot and confocal microscopy. (Fig. 6c and d). Treatment with ND-PTX-Cet enhanced the cellular uptake ability in the HCT116 cells but not in the SW620 cells (Fig. 6e and f). ND-PTX-Cet enhanced the cell death in HCT116 cells but had no significant effect in the SW620 cells (Fig. 6g). Besides, ND-PTX-Cet (green) can selectively bind to EGFR (Fig. 6h). Moreover, the EGFR protein expression of HCT116 cells was reduced by transfection with EGFR siRNA (Fig. 7a). The depletion of EGFR proteins by EGFR siRNA significantly reduced cell death by comparing with EGFR siRNA in the ND-PTX-Cet treated cells (Fig. 7b and c).
ND-PTX-Cet inhibits the xenografted human drug-resistant tumors in nude mice
To compare the antitumor activity between ND-PTX and ND-PTX-Cet, the HCT116-luc2 cells were subcutaneously inoculated into the right flank for 7 to 10 days and then treated with 20 mg/kg of Cet, 20 mg/kg of ND-PTX and ND-PTX-Cet three times for every 3 days. The luminescence signal of CRC tumors was reduced in the ND-PTX-Cet treatment groups by comparing to the control and ND-PTX treatment groups (Fig. 8a and b). However, the body weight of control group and drug-treated mice were not altered (Fig. 8c). The histological analysis by H&E staining revealed a widespread cystic space inside tumor due to tumor destruction by ND-PTX-Cet treatment (Fig. 8d). ND-PTX-Cet significantly increased the protein levels of p-H3S10 and the active forms of caspase 3 in the xenografted colon tumors by comparing with control or ND-PTX groups (Fig. 8d and e).
Discussion
The use of nanocarriers as drug delivery systems provide the opportunities to improve the efficacy of cancer therapy44,45,46. Various chemotherapeutic drugs can be linked to NDs35, 40, 47,48,49,50. ND-conjugated PTX has shown great promise in drug delivery and tumor blockage35, 40, 41. In this study, ND-PTX effectively inhibited CRC cell growth in cellular and animal models. Furthermore, the co-delivery of PTX and Cet by ND enhanced the mitotic catastrophe and tumor inhibition in the drug-resistance of CRC in vitro and in vivo.
The resistance to chemotherapy is acquired after treatment in cancer patients. ND is a promising nanomaterial for delivering chemotherapeutic drugs. ND-carried drugs could overcome drug efflux and multi-drug resistance to block tumors51, 52. ND delivered drugs to cancer cells primarily by endocytosis, which can bypass the multiple drug resistance (MDR) proteins. NDs can be taken by cancer cells through macropinocytosis and clathrin-mediated endocytosis20. ND conjugated with daunorubicin has been reported to be better performance in drug resistant leukemia cells52. ND as drug delivery system may improve drug retention and treatment efficacy in those chemoresistance tumors. Besides, ND-PTX-Cet exerted anticancer ability in drug-resistant K-Ras mutation of HCT116 CRC cells. We suggest that ND-PTX-Cet can overcome several drug-resistant forms in human cancers.
The phosphorylation of histone 3 (Ser10) (p-H3S10) is a hallmark of mitosis that begins during prophase, reaches maximum levels in metaphase43. Mitotic catastrophe has been accompanied by apoptosis induction17. The levels of p-H3S10 plays pivotal role in regulation of apoptosis and mitotic catastrophe53,54,55,56. PTX is a microtubule inhibitor by stabilizing the microtubule polymerization, which leads to mitotic catastrophe13,14,15. ND displayed fluorescence property without photobleaching19, 24, 26, 57. The intracellular location and uptake ability of ND-PTX can be detected by confocal microscope or flow cytometer. Previously, we showed that ND delivered into lysosomes through the selective autophagy pathway57. The uptake ability of ND-PTX is correlated to the anticancer activity of PTX in inducing mitotic catastrophe. ND-PTX increased the p-H3S10 proteins in the CRC cells and xenografted human tumor tissues in nude mice. Moreover, ND-PTX induced the apoptotic caspase 3 activation and the cleavage of PARP proteins. PARP is a key substrate for caspase 3 that was cleaved when cells undergo apoptosis58. These results demonstrate that ND-PTX can deliver into cancer cells to induce the mitotic catastrophe and apoptosis in human CRC.
Cet is a monoclonal antibody of EGFR that can provide metastatic CRC therapy7, 8. Cet can block EGFR function by binding to the extracellular domain of EGFR9. Conjugation of ND-PTX with Cet could specifically bind on the EGFR-positive CRC cells to enhance the mitotic blockage and apoptosis induction. ND-PTX-Cet markedly decreased tumor growth in the human EGFR-expressed CRC xenograft tumors of nude mice. Moreover, ND-PTX-Cet induced the persisted expression of p-H3S10 and active caspase 3 proteins for the mitotic catastrophe and apoptosis induction in vitro and in vivo.
In conclusion, we demonstrated that the new formulation of ND-PTX-Cet enhanced mitotic catastrophe, apoptosis induction and tumor inhibition. ND-PTX-Cet may develop a novel nanocomposite for the human CRC therapy.
Methods
Reagents and antibodies
Propidium iodide (PI), 3-(4,5-dimethyl-thiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT), Hoechst 33258, and the Cy3-labeled mouse anti-β-tubulin (c-4585) were purchased from Sigma Chemical Co. (St Louis, MO, USA). Anti-poly(ADP-ribose) polymerase (PARP) antibody was purchased from Cell Signaling Technology Inc. (Beverly, MA). Anti-caspase 3 antibody was purchased from BioVision (BioVision, Inc., Mountain View, CA). Anti-actin (I-19) antibody, goat anti-rabbit IgG horseradish peroxidase, goat anti-mouse IgG horseradish peroxidase and EGFR siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-phospho-histone H3 (Ser10) (p-H3S10) was purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).
Preparation of ND-PTX and ND-PTX-Cet
Paclitaxel was purchased from Tokyo Chemical Industry Co. (Ltd. Japan). Powdered ND particles with diameters of 3–5 nm were purchased from Nanostructured and Amorphous Materials Inc. (Houston, TX, USA). Initial chemical treatment of ND powders by carboxylation was carried out according to standard procedure35. Briefly, the ND particles were stirred in a 3:1 (v/v) mixture of concentrated HCl and HNO3 at room temperature for three days, then diluted with distillated deionized H2O (DDW) and separated by centrifugation at 900 rpm. After centrifugation, the pellets were extensively rinsed with DDW three times. The chemical synthetic procedure for the conjugation of ND and paclitaxel (PTX) was synthesized as described previously35. Cetuximab (Cet) was purchased from Merck Serono (Darmstadt, DE). For conjugation of ND-PTX and Cet, 10 µg of ND-PTX was incubated with 2.5 µg of Cet to form the ND-PTX-Cet complexes in DDW at 4 °C for 15 min. To avoid the unconjugated Cet, the ND-PTX-Cet complexes were centrifuged at 10000 rpm for 10 min at 4 °C in DDW. Thereafter, the pellets of ND-PTX-Cet complexes were collected and washed with DDW twice. For cellular and animal experiments, the concentrations of ND, ND-PTX and ND-PTX-Cet were freshly prepared with DDW for treatment in laminar flow.
Cell lines and cell culture
RKO (ATCC number: CRL-2677) was a colorectal carcinoma cell line that expressed wild type EGFR and K-Ras. HCT116 (ATCC number: CCL-247) was a colorectal carcinoma cell line that expressed wild type EGFR but carried K-Ras mutation. SW620 was a colorectal carcinoma cell line that did not express the EGFR proteins. RKO cells were cultured in DMEM medium (Gibco, Life Technologies, Grand Island, NY, USA). HCT116 cells were maintained in McCoy’s 5 A medium (Gibco, Life Technologies). SW620 were maintained in L-15 medium (Gibco, Life Technologies). The complete medium was supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 μg/mL streptomycin and sodium bicarbonate. These cells were maintained at 37 °C and 5% CO2 in a humidified incubator (310/Thermo, Forma Scientific, Inc., Marietta, OH).
Cell viability assays
Briefly, the cells were plated in 96-well plates at a density of 1 × 104 cells/well for 16–20 h. Then the cells were treated with ND or ND-conjugates in complete medium. At the end of treatment, the medium was replaced and the cells were incubated with 0.5 mg/mL of MTT in complete DMEM medium for 4 h. The viable cells converted MTT to formazan that generated a blue-purple color when dissolved in DMSO. The intensity of formazan was measured at 565 nm using a plate reader (VERSAmax, Molecular Dynamics, Sunnyvale, CA). The relative percentage of cell viability was calculated by dividing the absorbance of treated cells by that of the control in each experiment.
Cell death assays
The cells were plated at a density of 1 × 106 cells per 60-mm Petri dish in complete medium for 16–20 h. Thereafter, the cells were treated with ND or ND-conjugates. After treatment, the cells were washed with PBS and re-cultured in fresh medium. Finally, the samples were mixed with the Accustain solution, which contained lysis solution and PI. The cell death number by PI staining was subjected to an automatic cell counter (ADAM-MC, NESMU-AMC-001E, Digital Bio, Korean).
Uptake ability of ND-conjugates in the cells by flow cytometry
The cells were plated at a density of 7 × 105 cells per 60-mm Petri dish in complete medium for 16–20 h. After treatment with ND-conjugates, the cells were collected and fixed with ice-cold 70% ethanol overnight at −20 °C. The samples were analyzed by a flow cytometer (FACSCalibur, BD Biosciences, San Jose, CA). A minimum of ten-thousand cells was analyzed. The fluorescence of NDs was excited with wavelength 488 nm and the emission was collected in the green light signal range. The fluorescence intensity was quantified by a CellQuest software (BD Biosciences).
Western blot
The cells were plated at a density of 1 × 106 cells per 60-mm Petri dish in complete medium for 16–20 h. Then the cells were treated with ND-conjugates at 37 °C. At the end of treatment, the cells were lysed in the ice-cold cell extract buffer (pH 7.6) containing 0.5 mM DTT, 0.2 mM EDTA, 20 mM HEPES, 2.5 mM MgCl2, 75 mM NaCl, 0.1 mM Na3VO4, 50 mM NaF, 0.1% Triton X-100. The protease inhibitors including 1 μg/mL aprotinin, 0.5 μg/mL leupeptin, and 100 μg/mL 4-(2-aminoethyl) benzenesulfonyl fluoride were added to the cell suspension. The lysate was vibrated for 30 min at 4 °C and centrifuged at 10,000 rpm for 10 min. The protein concentrations were determined by the BCA protein assay kit (Pierce, Rockford, IL). The protein samples were separated on 8–12% sodium dodecyl sulfatepolyacrylamide gels and electrophoretic transfer of proteins onto polyvinylidene difluoride (PVDF) membranes. The PVDF membranes were blocked overnight at 4 °C using blocking buffer that contained 5% non-fat dried milk in solution with 50 mM Tris/HCl (pH 8.0), 2 mM CaCl2, 80 mM sodium chloride, 0.05% Tween 20 and 0.02% sodium azide. The membranes were sequentially hybridized with primary antibody and followed with a horseradish peroxidase-conjugated secondary antibody. The protein bands were visualized with an enhanced chemiluminescence assay (SuperSignal™ West Pico Chemiluminescent Substrate; Life Technologies). The gel digitizing software, Un-Scan-It gel (Ver. 6.1, Silk Scientific, Inc., Orem, UT), was used for semi-qualification.
Immunofluorescence staining and confocal microscopy
The cells were cultured on coverslips, which were kept in 35-mm Petri dish at a density of 5 × 105 per well for 16–20 h. After treatment with or without ND-conjugates, the cells were washed with PBS. The cells were fixed with 4% paraformaldehyde solution overnight at 4 °C. Then the cells were washed three times with PBS and non-specific binding sites were blocked in PBS containing 10% FBS and 0.3% Triton X-100 for 1 h at 37 °C. Thereafter, the cells were separately incubated with rabbit anti- p-H3S10 (1:100) antibody in PBS containing 10% FBS overnight at 4 °C, and washed three times with 0.3% Triton X-100 in PBS. Then the cells were incubated with anti-rabbit IgG-Hylite 488 (1:100) in PBS containing 10% FBS for 1 h at 37 °C, and washed three times with 0.3% Triton X-100 in PBS. The β-tubulin and nuclei were stained with the Cy3-labeled anti-β-tubulin (1:100) and Hoechst 33258 (Sigma Chemical Co., St. Louis, Mo), respectively. The samples were examined under a Multiphoton Confocal Microscope System (TCS-SP5-X AOBS, Leica, Germany).
Mitotic index analysis
The mitotic arrest cells following treatment with or without ND-conjugates were counted by mitotic index. The adherent cells were cultured on coverslips in a 60-mm Petri dish for 16–20 h before treatment. After treatment, the cells were carefully and gently washed with PBS (pH 7.4) to avoid the loss of mitotically round-up cells, and then fixed with 4% paraformaldehyde solution in PBS for one hour at 37 °C. The β-tubulin was stained with the Cy3-labeled mouse anti-β-tubulin (1:50) for 30 min at 37 °C. The nuclei were stained with 2.5 μg/mL Hoechst 33258 for 30 min. The mitotic cells showed round-up morphology, compact chromosomes, spindle formation, and contained a complete cell membrane but did not produce the cell membrane blebbing or the formation of apoptotic bodies. Mitotic index was determined by the percentage of mitotic cell number/total counted cells.
Sub-G1 fraction analysis
The cells were plated at a density of 7 × 105 cells per 60-mm Petri dish in complete medium for 16–20 h. After drug treatment, the cells were collected and fixed with ice-cold 70% ethanol overnight at −20 °C. Thereafter, the cell pellets were treated with 4 μg/mL PI solution, which contained 1% Triton X-100 and 100 μg/mL RNase for 30 min. To avoid cell aggregation, the samples were filtered through a nylon mesh membrane. A minimum of ten thousand cells in each sample was analyzed by CellQuest software in flow cytometer (FACSCalibur, BD Biosciences). The percentage of sub-G1 fractions was quantified by ModFit LT software (Ver. 2.0 and Ver. 3.2, BD Biosciences).
Annexin V-PI staining
The cells were plated in 60-mm Petri dish at a density of 7 × 105 cells/well for 16–20 h. Then the cells were treated with or without ND-conjugates in complete medium. Thereafter, the cells were collected and suspended in 1x binding buffer and then added 5 μl of Annexin V-FITC and 50 μg/mL PI. The samples were incubated at room temperature for 5 min in the dark and analyzed by flow cytometer (FACSCalibur, BD Biosciences). The cells shows Annexin V+/PI− indicated at the early stage apoptosis. The Annexin V+/PI+ indicated the late stage apoptosis. The percentage of Annexin V-PI staining cells was quantified from a minimum of ten thousand cells by CellQuest software (BD Biosciences).
Time-lapse observation of apoptosis induction
To observe the real-time formation of mitotic catastrophe and apoptosis by ND-conjugates, the cells were treated with ND-conjugates and then immediately observed by a live cell imaging microscope system for 24 h record (OLYMPUS IX71, Japan). The pictures and videos were edited by DP manager software (Ver. 3.3.1, OLYMPUS).
Xenograft human CRC tumors in nude mice
The BALB/cAnN.Cg-Foxn1 nu/CrlNarl mice (4-week-old male) were obtained from the Laboratory Animal Center of NAR Labs (NAR Labs, Taipei, Taiwan). After a week for environmental adaption, the mice were established solid human colon tumors by subcutaneous injection of 2 × 106 RKO cells. After 10 days, the mice bearing RKO xenografted tumors were treated with vehicle (PBS) or 50 mg/kg of ND-PTX by every 3 days for three times. The growth ability of tumors in the mice was measured by a digital caliper every three days and calculated by the following formula: (length) × (width)2 × 0.5. The tumors volumes were continuously measured until the mice were sacrificed. The Committee of Animal Center of National Chiao Tung University approved all animal studies and experimental protocols. All the methods involving animals were carried out in accordance with the approved guidelines.
Time-lapse observation of human CRC tumors in nude mice
The HCT116-luc2 cell line was purchased from PerkinsElmer Inc. (Waltham, MA). The BALB/cAnN.Cg-Foxn1 nu/CrlNarl mice (4 to 6 week-old male) were obtained from the Laboratory Animal Center of NAR Labs (NAR Labs, Taipei, Taiwan). The Solid HCT116-luc2 flank tumors in mice were established by subcutaneous injection of 2 × 106 cells. After 7 to 10 days inoculation, the mice bearing xenografted colorectal tumors were received 20 mg/kg of Cet, ND-PTX or ND-PTX-Cet. For the assessment of drug delivery in nude mice, the mice were anesthetized with 2% isoflurane and inoculated 100 μL 50 mM luciferin as substrate to emit luminescence and observed by IVIS spectrum imaging system (Xenogen IVIS Spectrum, PerkinElmer, Waltham, MA). Photographic and luminescence images were taken at constant exposure time. The acquired images and the luminescence intensity of harvested colorectal tumors were analyzed by Living Image® (Caliper Life Science).
Tissue homogenizing assays
The harvested tumor tissues from sacrificed mice were collected in the ice-cold cell extract buffer (pH 7.6), which contained 0.5 mM DTT, 0.2 mM EDTA, 20 mM HEPES, 2.5 mM MgCl2, 75 mM NaCl, 0.1 mM Na3VO4, 50 mM NaF, 0.1% Triton X-100. The total cellular protein extracts were prepared. The protease inhibitors including 1 μg/mL aprotinin, 0.5 μg/mL leupeptin, and 100 μg/mL 4-(2-aminoethyl) benzenesulfonyl fluoride were added to the samples. The samples were homogenized by homogenizer (Model Pro 200, PRO Scientific Inc., Oxford, CT). The lysates were centrifuged at 10,000 rpm at 4 °C for 10 min. The protein concentrations were determined by the BCA protein assay kit (Pierce, Rockford, IL). The samples were further subjected to western blot analysis.
Immunohistochemistry
Immunohistochemical staining was performed at the Pathology Core Laboratory, National Health Research Institutes in Taiwan. The tissue sections in slides were treated by xyline for deparaffinization and followed by 95 °C antigen retrieval in commercial Tris-base buffer with boric acid and ethylene-diamine- tetraacetic acid (Cell Conditioning 1, Roche, Rotkreuz, Switzerland) for 30 minutes. Then the samples were incubated with primary antibody for phospho-H3S10 with a dilution of 1:50 and Caspase 3 with a dilution of 1:200 overnight at room temperature. The detection was performed by the Ventana Discovery XT staining system with ultraView Universal DAB detection kit (Ventana Medical Systems, Inc, Tucson, AZ) according to the manufacturer’s protocol.
Statistical analysis
Each experiment was repeated at least three times. Data were analyzed using Student’s t-test or analysis of variance (a comparison of multiple groups), and a p value of <0.05 was considered statistically significant in each experiment.
References
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30 (2016).
Jemal, A. et al. Cancer statistics, 2005. CA Cancer J Clin 55, 10–30 (2005).
McWilliams, R. R. & Erlichman, C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 48, 1632–50 (2005).
Meyerhardt, J. A. & Mayer, R. J. Systemic therapy for colorectal cancer. N Engl J Med 352, 476–87 (2005).
Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408–17 (2009).
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360, 563–72 (2009).
Brand, T. M., Iida, M. & Wheeler, D. L. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11, 777–92 (2011).
Tabernero, J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5, 203–20 (2007).
Yewale, C., Baradia, D., Vhora, I., Patil, S. & Misra, A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34, 8690–707 (2013).
Wheeler, D. L. et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944–56 (2008).
Li, C., Iida, M., Dunn, E. F., Ghia, A. J. & Wheeler, D. L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801–3813 (2009).
Stanton, R. A., Gernert, K. M., Nettles, J. H. & Aneja, R. Drugs That Target Dynamic Microtubules: A New Molecular Perspective. Med Res Rev 31, 443–481 (2011).
Portugal, J., Mansilla, S. & Bataller, M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des 16, 69–78 (2010).
Bharadwaj, R. & Yu, H. T. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23, 2016–2027 (2004).
Spencer, C. M. & Faulds, D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48, 794–847 (1994).
Vitale, I., Galluzzi, L., Castedo, M. & Kroemer, G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12, 384–391 (2011).
Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825–2837 (2004).
Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 15, 1153–62 (2008).
Liu, K. K., Cheng, C. L., Chang, C. C. & Chao, J. I. Biocompatible and detectable carboxylated nanodiamond on human cell. Nanotechnology 18, 325102 (2007).
Liu, K. K., Wang, C. C., Cheng, C. L. & Chao, J. I. Endocytic carboxylated nanodiamond for the labeling and tracking of cell division and differentiation in cancer and stem cells. Biomaterials 30, 4249–59 (2009).
Yu, S. J., Kang, M. W., Chang, H. C., Chen, K. M. & Yu, Y. C. Bright fluorescent nanodiamonds: no photobleaching and low cytotoxicity. J Am Chem Soc 127, 17604–5 (2005).
Lechleitner, T. et al. The surface properties of nanocrystalline diamond and nanoparticulate diamond powder and their suitability as cell growth support surfaces. Biomaterials 29, 4275–84 (2008).
Chang, I. P., Hwang, K. C. & Chiang, C. S. Preparation of fluorescent magnetic nanodiamonds and cellular imaging. J Am Chem Soc 130, 15476–81 (2008).
Lien, Z. Y. et al. Cancer cell labeling and tracking using fluorescent and magnetic nanodiamond. Biomaterials 33, 6172–85 (2012).
Eldawud, R. et al. Combinatorial approaches to evaluate nanodiamond uptake and induced cellular fate. Nanotechnology 27, 085107 (2016).
Vaijayanthimala, V. et al. The long-term stability and biocompatibility of fluorescent nanodiamond as an in vivo contrast agent. Biomaterials 33, 7794–802 (2012).
Igarashi, R. et al. Real-time background-free selective imaging of fluorescent nanodiamonds in vivo. Nano Lett 12, 5726–32 (2012).
Mohan, N., Chen, C. S., Hsieh, H. H., Wu, Y. C. & Chang, H. C. In vivo Imaging and toxicity assessments of fluorescent nanodiamonds in Caenorhabditis elegans. Nano Lett 10, 3692–3699 (2010).
Haziza, S. et al. Fluorescent nanodiamond tracking reveals intraneuronal transport abnormalities induced by brain-disease-related genetic risk factors. Nat Nanotechnol 12, 322–328 (2017).
Yang, W. et al. DNA-modified nanocrystalline diamond thin-films as stable, biologically active substrates. Nat Mater 1, 253–7 (2002).
Ushizawa, K. et al. Covalent immobilization of DNA on diamond and its verification by diffuse reflectance infrared spectroscopy. Chem Phys Lett 351, 105–108 (2002).
Cheng, C. Y. et al. Direct and in vitro observation of growth hormone receptor molecules in A549 human lung epithelial cells by nanodiamond labeling. Appl Phy Lett 90, 163903 (2007).
Krueger, A., Stegk, J., Liang, Y., Lu, L. & Jarre, G. Biotinylated nanodiamond: simple and efficient functionalization of detonation diamond. Langmuir 24, 4200–4 (2008).
Mochalin, V. N., Shenderova, O., Ho, D. & Gogotsi, Y. The properties and applications of nanodiamonds. Nat Nanotechnol 7, 11–23 (2012).
Liu, K. K. et al. Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy. Nanotechnology 21, 315106 (2010).
Zhang, X. Q. et al. Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv Mater 23, 4770–5 (2011).
Khalid, A., Mitropoulos, A. N., Marelli, B., Tomljenovic-Hanic, S. & Omenetto, F. G. Doxorubicin loaded nanodiamond-silk spheres for fluorescence tracking and controlled drug release. Biomed Opt Express 7, 132–47 (2016).
Chao, J. I. et al. Nanometer-sized diamond particle as a probe for biolabeling. Biophys J 93, 2199–208 (2007).
Reineck, P. et al. Bright and photostable nitrogen-vacancy fluorescence from unprocessed detonation nanodiamond. Nanoscale 9, 497–502 (2017).
Hsieh, Y. H., Liu, K. K., Sulake, R. S., Chao, J. I. & Chen, C. Microwave-assisted efficient conjugation of nanodiamond and paclitaxel. Bioorg Med Chem Lett 25, 2074–7 (2015).
Lim, D. G., Jung, J. H., Ko, H. W., Kang, E. & Jeong, S. H. Paclitaxel-Nanodiamond Nanocomplexes Enhance Aqueous Dispersibility and Drug Retention in Cells. ACS Appl Mater Interfaces 8, 23558–67 (2016).
Wang, F. & Higgins, J. M. Histone modifications and mitosis: countermarks, landmarks, and bookmarks. Trends Cell Biol 23, 175–84 (2013).
Prigent, C. & Dimitrov, S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 116, 3677–85 (2003).
Suh, W. H., Suslick, K. S., Stucky, G. D. & Suh, Y. H. Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol 87, 133–170 (2009).
Tada, H., Higuchi, H., Wanatabe, T. M. & Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 67, 1138–44 (2007).
Wang, X. et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 3, 3165–74 (2009).
Li, X. X. et al. TAT-conjugated nanodiamond for the enhanced delivery of doxorubicin. J Mater Chem 21, 7966–7973 (2011).
Li, J. et al. Nanodiamonds as intracellular transporters of chemotherapeutic drug. Biomaterials 31, 8410–8418 (2010).
Guan, B., Zou, F. & Zhi, J. F. Nanodiamond as the pH-Responsive Vehicle for an Anticancer Drug. Small 6, 1514–1519 (2010).
Huang, H., Pierstorff, E., Osawa, E. & Ho, D. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett 7, 3305–14 (2007).
Chow, E. K. et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 3, 73ra21 (2011).
Man, H. B. et al. Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia. Nanomedicine 10, 359–69 (2014).
Fullgrabe, J., Hajji, N. & Joseph, B. Cracking the death code: apoptosis-related histone modifications. Cell Death Differ 17, 1238–43 (2010).
Baek, S. H. When signaling kinases meet histones and histone modifiers in the nucleus. Mol Cell 42, 274–284 (2011).
Liokatis, S. et al. Phosphorylation of histone H3 Ser10 establishes a hierarchy for subsequent intramolecular modification events. Nat Struct Mol Biol 19, 819–23 (2012).
Waring, P., Khan, T. & Sjaarda, A. Apoptosis induced by gliotoxin is preceded by phosphorylation of histone H3 and enhanced sensitivity of chromatin to nuclease digestion. J Biol Chem 272, 17929–36 (1997).
Liu, K. K. et al. Ubiquitin-coated nanodiamonds bind to autophagy receptors for entry into the selective autophagy pathway. Autophagy 13, 187–200 (2017).
Acehan, D. et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 9, 423–32 (2002).
Acknowledgements
This work was supported by grants from the Ministry of Science and Technology (MOST 103–2627-M-009–004, 104–2627-M-009–003 and 105–2627-M-009–002) and the collaboration of National Chiao Tung University and Mackay Memorial Hospital (MMH-CT-10301) in Taiwan. The authors also thank the core facilities of Multiphoton and Confocal Microscope System (MCMS) and In Vivo Imaging System (IVIS) in the National Chiao University, Hsinchu, Taiwan.
Author information
Authors and Affiliations
Contributions
J.-I.C. guided this study and supplied materials and equipment, Y.-W.L., W.-S.L., J.-L., K.-K.L., E.-N.R., T.-H.C, H.-C.C., C.-C.W. and L.Y.L. designed and conducted experiments, J.-L. helped clinical relevant and therapeutic application, Y.-W.L. and C.C. assisted the ND-conjugates preparation, Y.-W.L., E.-N.R., W.-S.L. and J.-I.C. wrote the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lin, YW., Raj, E., Liao, WS. et al. Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. Sci Rep 7, 9814 (2017). https://doi.org/10.1038/s41598-017-09983-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-017-09983-8
This article is cited by
-
Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance
Cancer and Metastasis Reviews (2023)
-
Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer
Journal of Nanobiotechnology (2022)
-
Nanodiamonds and their potential applications in breast cancer therapy: a narrative review
Drug Delivery and Translational Research (2022)
-
Mechanisms of cancer cell death induction by paclitaxel: an updated review
Apoptosis (2022)
-
Detonation Nanodiamonds as Promising Drug Carriers
Pharmaceutical Chemistry Journal (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.